A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

Leukemia, Published online: 10 January 2020; doi:10.1038/s41375-019-0700-9A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

Source: Leukemia - January 9, 2020 Category: Hematology Authors: G. A. Horne J. Stobo C. Kelly A. Mukhopadhyay A. L. Latif J. Dixon-Hughes L. McMahon P. Cony-Makhoul J. Byrne G. Smith S. Koschmieder T. H. Br Ümmendorf P. Schafhausen P. Gallipoli F. Thomson W. Cong R. E. Clark D. Milojkovic G. V. Helgason L. Foroni F. Source Type: research